Multiclinic controlled trial of diltiazem for Prinzmetal's angina

The American Journal of Medicine
J S SchroederR N MacAlpin

Abstract

To assess the efficacy of a new calcium entry blocker, diltiazem (Cardizem), for prophylaxis of Prinzmetal's angina, 48 patients were studied in randomized, multiple crossover multiclinic study (2 weeks single-blind, 8 weeks double-blind). Diltiazem dosage in one crossover phase was 120 mg per day; in the other, 240 mg per day. Therapeutic response was measured by patients' diary records of angina frequency and nitroglycerin tablet consumption. Treatment with 120 mg of diltiazem per day reduced angina by 41 percent from the entry placebo period and 20 percent from the paired placebo period (p less than 0.005). Treatment with 240 mg of diltiazem per day reduced angina frequency by 68 percent from the entry placebo period and 43 percent from the paired placebo period (p less than 0.01). There were similar reductions in nitroglycerin consumption. Adverse experiences that may have been related to the medication were noted in only 5 percent of patients. There were no alterations in blood pressure or heart rate. The PR interval increased 3 percent at the 240 mg dosage level. We conclude that diltiazem is an effective and safe agent for control of symptoms of Prinzmetal's angina.

References

Jan 1, 1977·Annual Review of Pharmacology and Toxicology·A Fleckenstein
Jun 5, 1980·The New England Journal of Medicine·E AntmanE Braunwald
Dec 1, 1980·The American Journal of Cardiology·S J RosenthalJ S Schroeder
Apr 9, 1981·The New England Journal of Medicine·S M JohnsonL D Hillis
Sep 1, 1959·The American Journal of Medicine·M PRINZMETALN BOR

❮ Previous
Next ❯

Citations

Jul 17, 1998·Journal of cardiology·T O Cheng
Jan 1, 1983·Pharmacology & Therapeutics·A G Ellrodt, B N Singh
Jun 1, 1983·Journal of the American College of Cardiology·J S SchroederB J McAuley
Jul 1, 1985·Journal of the American College of Cardiology·J S SchroederJ A Hemberger
Feb 1, 1987·Journal of the American College of Cardiology·X E PridaE Scott
Jan 1, 1985·Acta Pharmacologica Et Toxicologica·J S Schroeder
Jan 1, 1985·Acta Pharmacologica Et Toxicologica·M A QuigleyB F McGraw
Jun 1, 1986·Journal of Clinical and Hospital Pharmacy·M J Kendall, J V Okopski
May 1, 1998·Clinical Cardiology·S Mayer, L D Hillis
Jan 1, 1988·Journal of Clinical Pharmacology·E N Prystowsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.